Russian Heart Failure Journal 2014year Therapeutic effect of nitric oxide exemplified by its inductor, nebivolol


To access this material please log in or register

Register Authorize
2014/№5

Therapeutic effect of nitric oxide exemplified by its inductor, nebivolol

Bulanova E. L., Drapkina O. M.
“I. M. Sechenov First Moscow State Medical University” MPH RF, Trubetskaya 8-2, Moscow, 119991

Keywords: NO-synthase isoforms, nebivolol, nitric oxide


DOI: 10.18087 / rhfj.2014.5.1967

Nitric oxide (NO) is one of the most important mediators functionally involved in various biological processes. NO indirectly induces relaxation of the muscle layer, which results in dilatation of blood vessels, broncho-pulmonary system, esophagus, Oddi’s sphincter, stomach, and small and large intestine. Reduction of vascular hypertension results in improvement of organ blood flow. Therefore, NO exerts cardio- and vasoprotective effects. Nebivolol modulates NO release from endothelial cells.
  1. Eu JP, Sun J, Xu L et al. The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell. 2000 Aug 18;102 (4):499–509.
  2. Буланова Е. Л. Особенности метаболизма оксида азота у больных, перенесших операцию коронарного шунтирования. Автореф. дис…. канд. мед. наук. Москва, 2007.
  3. Ивашкин В. Т., Драпкина О. М. Клиническое значение оксида азота и белков теплового шока. – М.: «ГЭОТАР-Медиа», 2001. – 88с.
  4. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999 Aug 15;43 (3):521–31.
  5. Winn RK, Harlan JM. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemostas. 2005;3 (8):1815–24.
  6. Преображенский Д. В., Сидоренко Б. А., Патарая С. А. Некрасова Н. И. Небиволол – β-адреноблокатор третьего поколения в лечении сердечно-сосудистых заболеваний. РМЖ. 2008;16 (5):277–84.
  7. Манухина Е. Б., Дауни Х. Ф., Маллет Р. Т., Малышев И. Ю. Защитные и повреждающие эффекты периодической гипоксии: роль оксида азота. Вестник Росс. АМН. 2007;2:25–33.
  8. Метельская В. А., Туманова Н. Г. Скриннинг-метод определения уровня метаболитов оксида азота в сыворотке крови. Клиническая лабораторная диагностика. 2005;6:15–8.
  9. Alison B, O`Donnell VB, Freeman BA. Nitric oxide regulation of free radical and enzyme-mediated lipid and lipoprotein oxidation. Aterioscler Thromb Vasc Biol. 2000 Jul;20 (7):1707–15.
  10. Andrews NP, Husain M, Dakak N, Quyyumi AA. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol. 2001 Feb;37 (2):510–6.
  11. Howlett JG. Nebivolol: Vasodilator properties and evidence for rele­vance in treatment of cardiovascular disease. Can J Cardiol. 2014 May;30 (5S): 29–37.
  12. Голиков П. П., Леменев В. Л., Ахметов В. В. и др. Характер взаимосвязи оксида азота с ангиотензинпревращающим ферментом и малоновым диальдегидом у больных с атерогенным стенозом внутренней сонной артерии. Клиническая медицина. 2004;7:15–9.
  13. Насырова А. Г. Оксид азота в механизмах регуляции насосной функции сердца крыс. Автореф. дис. … канд. мед. наук. Казань, 2004.
  14. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003 Jan;83 (1):59–115.
  15. Falciani M, Rinaldi B, D’Agostino B et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001 Dec;38 (6):922–9.
  16. Patrascu N. Diastolic heart failure in hypertension: possible preventive benefits of nebivolol beyond lowering blood pressure. Maedica (Buchar). 2013 Sep;8 (3):285–9.
  17. Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs. 2006;66 (10):1389–409.
  18. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38 (Suppl 3):13–6.
  19. Zhang Z, Ding L, Jin Z et al. Nebivolol protects against myocardial infarction injury via stimulation of beta 3‑adrenergic receptors and nitric oxide signaling. PLoS One. 2014 May 21;9 (5):e98179.
  20. Tendera M. Epidemiology, treatment and guidelines for the treatment of heart failure in Europe. Eur Heart J (Suppl). 2005 Oct;7 (J): 5–9.
  21. Stoschitzky K, Stoschitzky G, Pieske B, Washer T. No evidence of nitrate tolerance caused by nebivolol. Ther Adv Cardiovasc Dis. 2014 Apr;8 (2):40–4.
  22. Bayar E, Ilhan G, Furat C et al. The effect of different β-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol. Eur J Vasc Endovasc Surg. 2014 Feb;47 (2):204–8.
Bulanova E. L., Drapkina O. M. Therapeutic effect of nitric oxide exemplified by its inductor, nebivolol. Russian Heart Failure Journal. 2014;15 (5): 312–315

To access this material please log in or register

Register Authorize
Ru En